OKYO

OKYO Pharma Limited
CAPPED RATING

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited (OKYO) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.1
EV / EBITDA -6.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -7.9%
Price Return 12M -49.3%
Catalyst Signal 0.00
Market Cap $73.5M
TTM Revenue N/A
Price / Sales N/A
ROE -263.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D- (0.9) C (2.2) C (2.5) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) D- (0.9) C (2.2) C+ (2.5) C+ (2.7) C (2.2)
2026-10-30 C+ (2.5) D- (1.0) C (2.3) C- (2.1) C+ (2.7) C- (2.1)
2026-10-23 C+ (2.5) D- (1.0) C (2.2) C (2.2) C+ (2.6) C- (2.1)
2026-10-16 C+ (2.5) D- (1.0) C (2.2) C (2.4) C+ (2.6) C- (2.1)
Page 1 of 3